Skip to main content
TipRanks
Go Ultimate75% OFF

Wendye Robbins Insider Profile

4 Followers

Wendye Robbins, former Director at RAPT Therapeutics, holds 27.50K shares in RAPT Therapeutics (Ticker: RAPT). Most recently, Wendye Robbins Bought 5,000 shares of RAPT Therapeutics on Mar 15, 2023 for an estimated value of $97.61K.

Wendye Robbins's Trading History

RAPT
RAPT Therapeutics
Mar 15, 2023―Informative Buy97.61K$1.60M
RAPT
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 15, 2023Informative Buy$97.61K5,000$19.52-55.50%
May 12, 2022Informative Buy$77.28K7,000$11.04+56.00%
Oct 19, 2021Informative Buy$15.35K500$30.70-36.10%
Oct 15, 2021Informative Buy$11.88K400$29.69-36.50%
Aug 25, 2021Informative Buy$62.56K2,000$31.28-5.40%

You May Also Like

Wendye Robbins insider profile FAQ

What is the percentage of profitable transactions made by Wendye Robbins?
The percentage of profitable transactions made by Wendye Robbins is 50%.
What is the average return per transaction made by Wendye Robbins?
The average return per transaction made by Wendye Robbins is 9.30%.
What stocks does Wendye Robbins hold?
Wendye Robbins holds: RAPT stocks.
What was Wendye Robbins’s latest transaction?
Wendye Robbins’s latest transaction was an Informative Buy of $97.61K.
What was Wendye Robbins's most profitable transaction?
Wendye Robbins’s most profitable transaction was an Informative Buy of RAPT stock on November 4, 2019. The return on the trade was 155.60%.
What is Wendye Robbins's role in RAPT Therapeutics?
Wendye Robbins's role in RAPT Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.